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Plaque-associated myeloid cells derive from resident
microglia in an Alzheimer’s disease model
Erin G. Reed-Geaghan1, Andrew L. Croxford2, Burkhard Becher2, and Gary E. Landreth3
Alzheimer’s disease (AD) is accompanied by a robust inflammatory response mediated by plaque-associated myeloid cells of
the brain. These cells exhibit altered gene expression profiles and serve as a barrier, preventing neuritic dystrophy. The origin of
these cells has been controversial and is of therapeutic importance. Here, we genetically labeled different myeloid
populations and unequivocally demonstrated that plaque-associated myeloid cells in the AD brain are derived exclusively from
resident microglia, with no contribution from circulating peripheral monocytes.
Introduction
Microglia arise from yolk sac erythromyeloid progenitors that
invade the neuroepithelium early in development (embryonic
day 8.5; Ginhoux et al., 2010; Schulz et al., 2012), where they
undergo self-renewal throughout life inmice (Askew et al., 2017;
Tay et al., 2017) and humans (Askew and Gomez-Nicola, 2018;
Re´u et al., 2017). Under normal conditions, there is no contri-
bution to the brain’s parenchymal myeloid cell population from
the periphery (Kierdorf and Prinz, 2017); however, yolk sac–
derived monocytes in the choroid plexus are gradually replaced
by peripheral monocytes from the bone marrow (Goldmann
et al., 2016). Microglia perform surveillance of the brain
through continuous extension and retraction of processes,
monitoring for tissue integrity, synapse function, and pathogens
(Davalos et al., 2005; Nimmerjahn et al., 2005).
Alzheimer’s disease (AD) is typified by a robust myeloid
cell–mediated inflammatory response that contributes to disease
pathogenesis. In the AD brain, an early increase in β amyloid
(Aβ) levels is followed by condensation into plaques within the
brain parenchyma. A subset of myeloid cells migrate to and
associate with these Aβ plaques, disrupting their homeostasis
and exhibiting progressive changes in their gene expression.
The conversion of plaque-associated cells from a “homeostatic”
state to a “disease-associated microglial” or “microglial neuro-
degeneration” phenotype is characterized by distinctive gene
expression signatures, including high levels of Trem2 expression
(Keren-Shaul et al., 2017; Krasemann et al., 2017). Importantly,
these plaque-associated myeloid cells effect a barrier function,
enveloping the plaques with their processes and phagocytically
remodeling the plaque, leading to its compaction, thereby pre-
venting neuritic dystrophy (Yuan et al., 2016).
The ontogenic origin of plaque-associated myeloid cells has
been controversial owing to ambiguity about whether they
originate from yolk sac–derived resident brain microglia or,
alternatively, peripheral blood–borne monocytes that infiltrate
the AD brain and subsequently acquire certain features shared
with resident microglia. This point is of some importance in
designing therapeutic interventions targeting this population of
cells. The suggestion that monocytes infiltrate the AD brain, as
occurs in other central nervous system disorders, and have
salutary effects on AD pathogenesis is not new (El Khoury and
Luster, 2008; Simard and Rivest, 2006; Simard et al., 2006). El
Khoury et al. (2007) reported peripheral myeloid cells infiltrated
the AD brain in a CCL2-dependent manner, and loss of CCR2 was
associated with fewer parenchymal microglia, increased plaque
burden, and increased Aβ peptide levels. In contrast, Naert and
Rivest (2012) reported that Ccr2 deletion had little effect on
plaque burden and promoted an increase in the abundance of
plaque-associated microglia exhibiting an anti-inflammatory
phenotype. Attempts to resolve this conflict have been compli-
cated by study design and technical considerations (Morganti
et al., 2014).
We previously argued that the plaque-associated myeloid
cells were likely derived from infiltrating peripheral “inflam-
matory” monocytes, owing to their sustained expression of
markers that identify these cells in the blood, i.e., CD45hi and
Ly6C, and low levels of the endogenous microglial marker
P2RY12 (Jay et al., 2015; Korin et al., 2017). The interpretation of
these data were confounded by evidence suggesting that mi-
croglial expression of these markers is altered in the context of
AD, and therefore they may not be definitive markers of cell
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ontogeny. Here, we have used inducible genetic markers to
definitively identify the ontogenic origin of plaque-associated
myeloid cells in the AD brain. Fate mapping reveals that
plaque-associated myeloid cells derive exclusively from the en-
dogenous yolk sac–derived microglia.
Results and discussion
In an effort to identify the ontogeny of plaque-associated mye-
loid cells as either resident microglia-derived or peripheral
monocytes that have infiltrated into the brain and migrated
through the parenchyma to plaques, we used genetic labeling
strategies to inducibly and irreversibly label each subset of
myeloid cells (Fig. 1 A). Selective expression of the fluorescent
marker tdTomato via tamoxifen-inducible Cx3cr1-CreERT2 (Yona
et al., 2013) exclusively labels resident microglia in the brain,
allowing for their identification apart from infiltrating
blood-borne macrophages. Similarly, we employed an inducible
Ccr2-driven Cre (Ccr2-CreERT2), which is highly expressed in
circulating Ly6Chi monocytes (Croxford et al., 2015), to inducibly
express tdTomato. These murine lines were crossed into the
5xFAD AD mouse model (Oakley et al., 2006), which exhibits
rapid plaque development over 2–8 mo.
The Cx3cr1-CreERT2; 5xFAD; ROSA26-tdTomato (Cx3cr1; 5x; R26)
mice were treated with tamoxifen at 1 mo of age to induce
tdTomato expression. Themicewere sacrificed at 2, 4, or 8mo of
age (Fig. 1 A). We performed immunohistochemistry (IHC) for
tdTomato plus CD45 or TREM2, twomolecules whose high levels
of expression are commonly associated with peripheral myeloid
cells. We found that virtually all CD45- and TREM2-positive cells
around plaques were tdTomato positive using the resident mi-
croglial driver Cx3cr1-CreERT2 (Fig. 1, B and D).
The Ccr2-CreERT2; 5xFAD; ROSA26-tdTomato (Ccr2; 5x; R26)
mice were induced to express tdTomato by tamoxifen treatment
for 28 d, starting at 1, 3, or 7 mo of age (Fig. 1 A). The sustained
tamoxifen treatment was required for the efficient labeling of
Figure 1. Plaque-associated myeloid cells are
resident, yolk sac–derived microglia. (A)
Schematic for tamoxifen exposure to drive ex-
pression of tdTomato in Cx3cr1CreERT2; 5xFAD;
ROSA26tdTomato (top, purple) or Ccr2CreERT2; 5xFAD;
ROSA26tdTomato (bottom, yellow) mice. Tamoxifen
treatment (TMX) is indicated by red arrows
(subcutaneous injection) or red bars (tamoxifen-
containing chow). m, month. (B–G) Represen-
tative confocal images of IHC for CD45 (B and C),
TREM2 (D and E), and Iba1 (F and G) in the su-
biculum at 8 mo of age in Cx3cr1CreERT2; 5xFAD;
ROSA26tdTomato (B, D, and F) and Ccr2CreERT2;
5xFAD; ROSA26tdTomato (C, E, and G) mice treated
with tamoxifen. Scale bars, 15 µm (bars in C, E,
and G apply to B, D, and F). (H) Quantification
of the fraction of Iba1+ cells expressing tdTomato
in the cortex, hippocampus, and thalamus in
Cx3cr1CreERT2; 5xFAD; ROSA26tdTomato (purple bars)
and Ccr2CreERT2; 5xFAD; ROSA26tdTomato (yellow bars)
mice treated with tamoxifen. Data presented as
mean ± SEM from six mice/genotype/age from
three or more independent experiments.
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circulating Ccr2+ monocytes, owing to their brief lifetimes in the
blood (Geissmann et al., 2003; Fig. S1), and over an interval in
which rapid plaque growth is occurring. We were unable to
detect any CD45+ and TREM2+ cells around plaques that were
positive for tdTomato (Fig. 1, C and E).
To ensure we did not miss any Ccr2-lineage cells migrating
into the brain, we performed IHC for Iba1, which detects both
endogenous microglia and monocytes that have infiltrated the
brain. We counted the fraction of Iba1+tdTomato+ cells
throughout the cortex, hippocampus, and thalamus (Fig. 1, F and
H) and found that >98% of the Iba1+ cells were tdTomato+ in
Cx3cr1; 5x; R26 mice treated with tamoxifen, while none of the
Iba1+ cells in Ccr2; 5x; R26 mice treated with tamoxifen were
tdTomato+ (Fig. 1, G and H). These data demonstrate that pa-
renchymal myeloid cells in the AD brain are resident, yolk
sac–derived microglia, with no additional contribution from
peripheral monocyte populations. Thus, the AD brain does not
elicit the engraftment of peripheral myeloid cells.
To confirm that the labeling of myeloid cells in the brain
was reflective of actual labeling and not due to Cx3cr1+-
labeled peripheral monocytes trafficking into the brain or a
failure to efficiently label Ccr2-lineage cells, we performed
flow cytometry to assess tdTomato expression in peripheral
monocyte populations from the blood or spleen (Fig. 2 A)
using previously described gating strategies (Croxford et al.,
2015) to identify monocytes (CD11b+CD115+, either Ly6Chi or
Ly6Clo).
Cx3cr1; 5x; R26 mice injected twice at 1 mo of age with ta-
moxifen exhibited some residual labeling of Ly6Clo monocytes
in the blood (Fig. 2 B) and spleen (Fig. 2 C) at 2 mo of age, but
it was absent by 4 and 8 mo of age. Ccr2; 5x; R26 mice on
tamoxifen-containing chow for 28 d before harvest at 2, 4, or
8 mo of age showed robust tdTomato expression in both Ly6Chi
and Ly6Clo monocytes in both the blood and spleen, irrespective
of 5xFAD genotype (Fig. 2 D). Furthermore, lineage-tracing
studies demonstrated that a fraction of monocytes at the
brain interfaces (i.e., choroid plexus and meninges) consist of
bone marrow–derived monocytes (Goldmann et al., 2016).
Choroid plexus monocytes initially arise from yolk sac pro-
genitors but are gradually replaced by bone marrow–derived
monocytes in a CCR2-dependent manner. Iba+ cells in the
choroid plexus and on the surface of the brain were assessed
for tdTomato expression, and a subset were found to be
tdTomato+ (Fig. 2 E), further validating labeling of peripheral
monocytes.
The origins and nature of the plaque-associated myeloid cells
in the AD brain have attracted considerable attention and en-
gendered substantial controversy owing to the florid and dis-
tinctive phenotypes adopted by these cells, which differ
dramatically from adjacent, uninvolved parenchymal microglia.
Moreover, this discussion has been influenced by the recent
revelation of the ontogenic origins of various macrophage pop-
ulations associated with the brain, which contravened conven-
tional understanding (Goldmann et al., 2016). The idea that
peripheral monocytes or macrophages might enter the AD brain
arose from earlier studies of other central nervous system dis-
orders, most prominentlymultiple sclerosis, inwhich peripheral
immune cells infiltrate the diseased brain and participate in
disease pathogenesis (Kierdorf and Prinz, 2017).
An influential study (El Khoury et al., 2007) reported that
knockout of the chemokine receptor CCR2 in a mouse model of
AD resulted in fewer plaque-associated myeloid cells and ac-
celerated disease progression and argued that bone marrow–
derived monocytes enter the brain through the vasculature,
migrate, and associate with amyloid plaques. The identification
of the infiltrates as peripherally derived hinged largely on their
expression of CD11b and CD45 (Korin et al., 2017; Mildner et al.,
2011). However, recent work has refuted this assertion (Mrdjen
et al., 2018). Transcriptomic studies (Keren-Shaul et al., 2017;
Krasemann et al., 2017) have allowed delineation of microglia
from macrophages and other immune cells, but have not been
able to resolve the issue of ontogenic origin of the plaque-
associated cells, owing to the rapid and diverse changes in my-
eloid cell gene expression in the brain microenvironment (Lund
et al., 2018).
The issue of whether peripheral monocytes can enter the AD
brain is of some significance, since therapeutically targeting
these cells is of potential interest. Indeed, approaches to blocking
their entry into the brain and treating circulating cells before
their entry have been suggested. Alternative proposals include
replacing endogenous microglia with peripheral macrophages
(Cronk et al., 2018; Shemer et al., 2018) or using these cells to
introduce molecules of interest into the brain (Bo¨ttcher et al.,
2019).
We previously argued that plaque-associated myeloid cells
were likely peripheral in origin (Jay et al., 2015), owing to their
high levels of CD45 and Ly6C expression by IHC. This conclusion
was challenged by Colonna and colleagues, who performed
parabiosis experiments and were unable to detect any periph-
eral myeloid cells in the AD brain (Wang et al., 2016). While
parabiosis models have the significant benefit over bone mar-
row grafts in determining myeloid cell origin, in that they do not
rely on methods that may compromise the blood–brain barrier
and therefore obscure the relative contribution of various cell
types, these studies still represent an artificial system that could
misrepresent the immune environment. We initiated our stud-
ies to provide an independent evaluation of this question using
an alternative experimental approach. The present data defini-
tively demonstrate that plaque-associated myeloid cells are ex-
clusively brain-resident microglia in the absence of potentially
confounding experimental conditions.
Materials and methods
Mice
5xFAD mice (Oakley et al., 2006; The Jackson Laboratory, MMRRC
34848-JAX)weremated to either homozygous CreERT2 Cx3cr1CreERT2
(Yona et al., 2013; Jackson 020940) or Ccr2CreERT2 (Croxford et al.,
2015)mice provided by B. Becher to generate Cx3cr1CreERT2/+; 5xFAD
or Ccr2CreERT2/+; 5xFAD mice, which were in turn mated to homo-
zygous tdTomato ROSA26tdTomato mice, producing experimental
Cx3cr1CreERT2/+; 5xFAD; R26tdTomato/+ and Cx3cr1CreERT2/+; wild type;
R26tdTomato/+ mice or Ccr2CreERT2/+; 5xFAD; R26tdTomato/+ mice and
Ccr2CreERT2/+; wild type; R26tdTomato/+ mice. Same-sex littermates
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were randomly assigned to control and experimental groups. Ex-
perimental mice were 2, 4, and 8 mo of age. All mice were main-
tained and experiments were performed in accordance with
Institutional Animal Care and Use Committee guidelines at Case
Western Reserve University.
Husbandry and housing conditions
Mice were ear-notched and genotyped by tail snipping at post-
natal day 18 (P18), weaned at P21, and housed in cages with
same-sex littermates under conditions approved by the Insti-
tutional Animal Care and Use Committee. Animals were geno-
typed using a PCR-based strategy suggested by the vendor for
Cx3cr1CreERT2, 5xFAD, and ROSA26tdTomato. Primers for Ccr2CreERT2
are available on request.
Tamoxifen administration
Tamoxifen (Sigma-Aldrich) was dissolved in corn oil to 5%
concentration and administered in 200-µl doses via two sub-
cutaneous injections 48 h apart (5 mg/dose) to Cx3cr1CreERT2/+;
5xFAD; R26tdTomato/+ and Cx3cr1CreERT2/+; wild type; R26tdTomato/+
mice at 1 mo of age. Tamoxifen-containing chow (400 mg/kg
citrate; Envigo, TD130860) was provided to Ccr2CreERT2/+; 5xFAD;
R26tdTomato/+mice and Ccr2CreERT2/+; wild type; R26tdTomato/+mice
for 28 d at 1, 3, or 7 mo of age, after which mice were euthanized.
For kinetic labeling studies, 4-mo-old Ccr2CreERT2/+; 5xFAD;
R26tdTomato/+mice and Ccr2CreERT2/+; wild type; R26tdTomato/+mice
were given tamoxifen-containing chow for 5 d and then eutha-
nized or put on normal chow until euthanasia 2 or 4 wk after
ending tamoxifen-containing chow.
Figure 2. Labeling of peripheral monocyte
populations following tamoxifen exposure.
(A) Representative flow sorting scheme for
tdTomato expression in Ly6Chi and Ly6Clo
monocytes from the spleen. FSC, forward scat-
ter; SSC, side scatter. (B and C) Fraction of
Ly6Chi and Ly6Clo monocytes in the blood (B) or
spleen (C) expressing tdTomato in Cx3cr1CreERT2;
ROSA26tdTomato mice at 2, 4, or 8 mo of age fol-
lowing tamoxifen or control injections at 1 mo of
age. Data presented as mean ± SEM from five or
more mice/age/treatment from three or more
independent experiments. (D) Fraction of Ly6Chi
and Ly6Clo monocytes expressing tdTomato in
Ccr2CreERT2; ROSA26tdTomato mice. Data presented
as mean ± SEM from ≥15 mice/age/treatment
from ≥3 independent experiments. TMX, ta-
moxifen. (E) Representative confocal images of
IHC for Iba1 and tdTomato in the choroid plexus
and on the brain surface in 8-mo-old Ccr2CreERT2;
5xFAD; ROSA26tdTomato mice treated with tamox-
ifen for 28 d. Scale bar, 15 µm.
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Tissue harvest and cell preparation
Mice were euthanized by cervical dislocation following iso-
fluorane (Henry Schein) anesthesia. Blood was collected by
cardiac puncture into sodium citrate (3.8% wt/vol) as an anti-
coagulant. RBC Lysis Buffer (BioLegend) was diluted to 1× and
used 9:1 to lyse blood cells for 10 min. Cells were pelleted and
washed in PBS and were then ready for staining with fluores-
cence cytometry antibodies. Spleens were dissected out and held
in 10% FBS/PBS on ice until processing into single cells for flu-
orescence cytometry. Tissue was mechanically homogenized
and passed through a 70-µm filter cell strainer, followed by
resuspension in 1× RBC Lysis Buffer. Lysis was stopped by
adding PBS, and cells were pelleted and washed for staining
with fluorescence cytometry antibodies. Brains were dissected
out and bisected along the midline, with one hemisphere
immersion-fixed in 4% paraformaldehyde (PFA)/PBS for IHC
and the other processed into single cells for fluorescence cy-
tometry. Briefly, tissue was mechanically homogenized and
passed through a 70-µm strainer, followed by 30/37/70% Percoll
(GE Healthcare) gradient centrifugation in PBS (vol/vol;
20,000 g for 20 min at room temperature without brakes), re-
moval of myelin with suction, and collection of cells from the 37/
70% interface, and washed in PBS. Samples were then ready for
staining with fluorescence cytometry antibodies.
Flow cytometry
Pooled portions of samples were used for unstained, single-
stained control, and isotype controls, whereas individual sam-
ples were stained with a master mix of antibodies. All cell
suspensions were incubated with FcR block (1:100; CD16/CD32,
clone 92; eBioscience; 14-0161-85) before staining. Blood cells
were stained using Alexa Fluor 700–conjugated CD11b cloneM1/70
(1:200; Thermo Fisher Scientific, 56-0112-82), allophycocyanin
(APC)-conjugated CD115 clone AFS98 (1:200; BioLegend,
135509), Alexa Fluor 488–conjugated Ly6C clone HK1.4 (1:200;
Thermo Fisher Scientific, 53-5932-80), phycoerythrin cyanine
(PEC) 5.5-conjugated Ly6G clone RB6-8C5 (1:200; eBioscience,
35-5931-82), PEC7-conjugated F4/80 clone BM8 (1:200; eBio-
science, 25-4801-82), or PEC7-conjugated CD3 clone 17A2 (1:200;
BioLegend, 100219), Alexa Fluor 488–conjugated CD4 clone
GK1.5 (1:200; eBioscience, 53-0041-82), and APC-conjugated
CD8b clone YTS156.7.7 (1:200; BioLegend, 126613) diluted in
flow buffer (FB; 0.2% 0.5 M EDTA, 2% FBS). Spleen cells were
stained using Alexa Fluor 700–conjugated CD11b clone M1/70
(1:200), APC-conjugated CD115 clone AFS98 (1:200), and Alexa
Fluor 488–conjugated Ly6C clone HK1.4 (1:200), or APC-
conjugated CD11b (1:200), Alexa Fluor 700–conjugated CD11c
clone N418 (1:200; Thermo Fisher Scientific, 56-0114-80), and
Alexa Fluor 488–conjugated MHCII clone M5/114.15.2 (1:200;
BioLegend, 107615) diluted in FB. Brain cells were stained using
Alexa Fluor 488–conjugated CD45 clone 30-F11 (1:200; Bio-
Legend, 103122) and APC-conjugated CD11b clone M1/70 (1:200)
in FB. After 30 min of surface staining on ice, cells were washed
in FB, fixed in 4% PFA/FB, resuspended in FB, and filtered
using Falcon tubes. Flow cytometry was performed using a BD
FACSAria SORP (Becton Dickinson) and analyzed with FlowJo
software (TreeStar). Standard, strict side scatter height versus
area was used to discriminate doublets and gate singlets. For-
ward scatter area versus side scatter area was used to gate cells.
Tissue processing and IHC
Brains were harvested as described above. One hemisphere was
postfixed overnight in 4% PFA, cryopreserved in 30% sucrose/
PBS, embedded in optimal cutting temperature compound, and
sectioned at 30 µm on a Leica CM 1950 cyostat. Sections were
permeabilized with PBS containing 0.1% Triton X-100 and in-
cubated in 1× Reveal Decloaker (Biocare Medical, RV1000) di-
luted in ddH2O for 10 min at 95–100°C for antigen retrieval,
followed by 30-min cooling. Sections were then incubated in
blocking buffer containing 5% normal goat serum and 0.3%
Triton X-100 in PBS at room temperature for 1 h. Primary an-
tibodies were diluted in blocking buffer, applied to sections, and
incubated overnight at 4°C. Primary antibodies included rabbit
anti-RFP (1:500; Rockland; 600-401-379), rat anti-CD45 clone
IBL-3/16 (1:500; Bio-Rad; MCA1388); biotinylated sheep anti-
TREM2 (1:200; R&D Systems; BAF1729), rat anti-Dectin1 clone
R1-8g7 (1:50; InvivoGen; mabg-mdect), goat anti-Iba1 (1:500;
Abcam; ab107159), mouse anti-Aβ clone 6E10 (1:1,000; Bio-
Legend; 803001), and rat anti-MHCII (I-A/I-E; 1:100; Thermo
Fisher Scientific; 14-5321-82). Primary antibodies were visualized
with the appropriate Alexa Fluor 488–, 546–, and 647–conjugated
secondary antibodies (1:1,000; Thermo Fisher Scientific) for 1 h at
room temperature. Cell nuclei were counterstained with DAPI,
and slices were mounted and coverslipped with ProLong Gold
(Thermo Fisher Scientific; P36930).
Microscope image acquisition and quantification
IHC was performed on eight evenly spaced medial to lateral
sections per animal. Confocal images were acquired at 63×, with
1-µm optical slices spanning the tissue depth on an LSM 800
microscope (Zeiss). Maximum projections were reconstructed
using ImageJ (National Institutes of Health).
Quantification of IHC experiments was conducted by ob-
servers blinded to tamoxifen treatment and 5xFAD genotype.
The number of Iba1+, CD45+, or MHCII+ cells positive for tdTo-
mato were manually scored from every 12th sagittal section
(8–10 sections/animal). Iba1+ cells were counted from three
cortical regions (motor, somatosensory, and visual cortex), the
hippocampus (subiculum, CA1, CA2, CA3), and thalamus at 40×
magnification. Values were summed across sections for each
animal to determine the fraction of each population that was
tdTomato+. Data are graphed as the mean ± SEM.
Statistical analysis
Prism (GraphPad) was used for all statistical analyses. Grubb’s test
with a cutoff of α = 0.05 was used to determine statistical outliers.
Statistical significance was determined using a two-way ANOVA
with Bonferroni post hoc analysis. Both male and female mice
were used in this study, and all groups were sex-matched for each
experiment. Each n represents a single biological replicate.
Online supplemental material
Fig. S1 illustrates the kinetics of labeled cell populations in Ccr2-
CreERT2mice following 5 d of tamoxifen treatment followed by a
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return to regular chow. These data show the short lifetime of
these circulating cells in the blood.
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Supplemental material
Figure S1. Kinetics of labeled peripheral monocytes using Ccr2-CreERT2. The fraction of monocytes (MOs; CD11b+CD115+), neutrophils (NPs;
CD11b+Ly6G+), and dendritic cells (DCs; CD11b+CD11c+MHCII+) expressing tdTomato immediately after 5 d of tamoxifen-containing chow, or following a 2 or 4-
wk return to normal chow. Data presented are mean ± SEM from eight mice/time point from three or more independent experiments.
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